This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: Regeneron, AT&T, AMETEK, Hershey Company and BGC
by Zacks Equity Research
Zacks.com featured highlights include: Regeneron, AT&T, AMETEK, Hershey Company and BGC
CHMP Reconfirms Negative Opinion for Sarepta's Exondys
by Zacks Equity Research
The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.
Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar
by Zacks Equity Research
Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.
5 Stocks With Robust Sales Growth Worth Adding to Portfolio
by Zacks Equity Research
Sales growth is an important metric for any company as it is a vital part of growth projections and is instrumental in strategic decision-making.
FDA Confirms Positive Safety Profile of Acadia's Nuplazid
by Zacks Equity Research
Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.
Zacks.com highlights: G-III Apparel Group, Target, Regeneron Pharmaceuticals, AMETEK and Xilinx
by Zacks Equity Research
Zacks.com highlights: G-III Apparel Group, Target, Regeneron Pharmaceuticals, AMETEK and Xilinx
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success
by Zacks Equity Research
Pipeline updates and data read-outs at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France comprise some of the key developments in the biotech sector this week.
5 Stocks Near 52-Week High With Scope for Further Upside
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels with room for further improvement.
Regeneron Gains on Eylea, Dupixent and Pipeline Progress
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.
Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
by Zacks Equity Research
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA
by Zacks Equity Research
The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.
Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine
by Zacks Equity Research
Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.
Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine
by Zacks Equity Research
Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?
by Zacks Equity Research
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Oracle, Intuit, Regeneron, Macy's and Deere
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Intuit, Regeneron, Macy's and Deere
Top Stock Reports for Oracle, Intuit & Regeneron Pharmaceuticals
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Intuit (INTU) and Regeneron Pharmaceuticals (REGN)
4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings
by Ekta Bagri
The biotech sector is expected to do well in the second half of 2018. Here we list four top biotech companies, which investors can add to their portfolio.
Top-Ranked Stocks That Crushed S&P 500 in Longest Bull Run
by Sweta Killa
We have presented five stocks for investors that have performed exceptionally well in the longest bull market and will likely continue their outperformance.
Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco
by Zacks Equity Research
The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.
Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) gets the FDA approval for the label expansion of its lead drug, Eylea as a treatment for wet AMD with a modified 12-week dosing schedule.